Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Profile Name||BRAF F595L|
|Gene Variant Detail|
|Relevant Treatment Approaches||MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor|
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|BRAF F595L||Advanced Solid Tumor||resistant||Vemurafenib||Preclinical - Cell culture||Actionable||In a preclinical study, treatment with Zelboraf (vemurafenib) did not reduce activation of Mek and Erk by BRAF F595L in transformed cells in culture (PMID: 26582644).||26582644|
|BRAF F595L||colorectal cancer||not predictive||Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab||Case Reports/Case Series||Actionable||In a clinical study, the combination of Vectibix (panitumumab) with FOLFOX as a first-line therapy resulted in a partial response with progression-free survival of 10.2 months in a patient with metastatic colorectal cancer harboring BRAF F595L (PMID: 31515458).||31515458|